Revlimid is indicated as a treatment for multiple myeloma and anemia due to myelodysplastic syndrome linked with a deletion in the long arm of the fifth chromosome.
In the trial, around 12 patients will be given Vacc-4x in conjunction with Revlimid, however other set of 12 patients will receive Vacc-4x alone.
The study aims to establish the ability of Vacc-4x in improving immune function in patients that fail to regain a healthy immune defense despite that their viral load is well controlled on conventional HIV-medicines (antiretroviral therapy – ART).
The study will also evaluate the effect of Revlimid on Vacc-4x’s ability to improve immune function.
Bionor CSO Maja Sommerfelt said the use of a therapeutic vaccine combined with modulation of the immune system resonates well with the current thinking in the scientific community.